AU5732290A - Antibody-oxidase conjugates with non-systemic substrates - Google Patents

Antibody-oxidase conjugates with non-systemic substrates

Info

Publication number
AU5732290A
AU5732290A AU57322/90A AU5732290A AU5732290A AU 5732290 A AU5732290 A AU 5732290A AU 57322/90 A AU57322/90 A AU 57322/90A AU 5732290 A AU5732290 A AU 5732290A AU 5732290 A AU5732290 A AU 5732290A
Authority
AU
Australia
Prior art keywords
systemic
antibody
substrates
oxidase
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57322/90A
Inventor
John D. Duncan
Frieder K. Hofmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brunswick Corp
Original Assignee
Brunswick Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brunswick Corp filed Critical Brunswick Corp
Publication of AU5732290A publication Critical patent/AU5732290A/en
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
AU57322/90A 1989-06-30 1990-03-21 Antibody-oxidase conjugates with non-systemic substrates Abandoned AU5732290A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37404889A 1989-06-30 1989-06-30
US374048 1989-06-30

Publications (1)

Publication Number Publication Date
AU5732290A true AU5732290A (en) 1991-01-17

Family

ID=23475040

Family Applications (1)

Application Number Title Priority Date Filing Date
AU57322/90A Abandoned AU5732290A (en) 1989-06-30 1990-03-21 Antibody-oxidase conjugates with non-systemic substrates

Country Status (3)

Country Link
EP (1) EP0449998A4 (en)
AU (1) AU5732290A (en)
WO (1) WO1991000108A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9021671D0 (en) * 1990-10-05 1990-11-21 Unilever Plc Delivery of agents
DE4233152A1 (en) 1992-10-02 1994-04-07 Behringwerke Ag Antibody-enzyme conjugates for prodrug activation
CA2354908A1 (en) 1998-12-11 2000-06-22 Unilever Plc Bleaching enzymes and detergent compositions comprising them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4496539A (en) * 1982-02-01 1985-01-29 Massachusetts Institute Of Technology Method for treating cancer using galactose-specific lectins
FR2523445A1 (en) * 1982-03-17 1983-09-23 Sanofi Sa NOVEL CONJUGATES ASSOCIATING, BY COVALENT BINDING, AN ENZYME AND ANTIBODY, AND DRUG ASSOCIATIONS USING THE SAME
WO1986001720A1 (en) * 1984-09-13 1986-03-27 Cytogen Corporation Antibody therapeutic agent conjugates
GB8528761D0 (en) * 1985-11-22 1985-12-24 Axon Healthcare Ltd Enzyme-coupled antibodies
WO1990003185A1 (en) * 1988-09-28 1990-04-05 Ideon Corporation Combination enzyme immunotherapeutics

Also Published As

Publication number Publication date
EP0449998A1 (en) 1991-10-09
EP0449998A4 (en) 1992-01-15
WO1991000108A1 (en) 1991-01-10

Similar Documents

Publication Publication Date Title
AU629940B2 (en) Glass composition
AU5748990A (en) Venoscope
AU5874690A (en) Octreotide-pamoate
AU627080B2 (en) Sulphonylaminocarbonyltriazolinones
AU623262B2 (en) Hydroxypropylamines
AU6673290A (en) Dipyridodiazepines
AU5382190A (en) Nutrient composition
AU631622B2 (en) Snow-vehicle
AU623780B2 (en) Chromanderivate
AU6206090A (en) Planar airstripline-stripline magic-tee
AU5403690A (en) Envelopes
AU5782590A (en) Thioxotetrazolines
AU5336690A (en) Leg-guard
AU6627590A (en) Doll-container
AU6839190A (en) Triazolylsulfonamides
AU5546090A (en) Antibody-lactate oxidase conjugates
AU5732290A (en) Antibody-oxidase conjugates with non-systemic substrates
AU6268590A (en) Aminophosphinates
AU6877391A (en) Display devices
AU4944090A (en) Cryoelectrosynthesis
AU3959089A (en) Turntable
AU5061490A (en) Bisphenethanolamines
AU5397590A (en) Bisacylethylamines
AU644371B2 (en) Anthracycline derivatives
AU637395B2 (en) Advertising device